Pancreatic cancer
Conditions
Interventions
Gold Standard:General Office of the National Health Commission, Guidelines for the Diagnosis and Treatment of Pancreatic Cancer (2022 Edition), as well as the AJCC 8th Edition Pancreatic Cancer Stagin
Index test:Histopathological examination and laboratory tests
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Pancreatic cancer patient group:; 1. voluntarily signed informed consent; 2. 18 years <= age <= 80 years; 3. histopathologically confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) or pancreatic adenocarcinoma; 4. patients with complete clinical case information, including age, pre-treatment blood test results such as CA19-9 and other important clinical information; Benign Disease Control Group:; 1. voluntarily signed informed consent; 2. 18 years <= age <= 80 years; 3. histopathological or imaging confirmed diagnosis of (any of the following) plasma cystadenoma of the pancreas, solid pseudopapillary tumour of the pancreas, chronic pancreatitis, cholelithiasis , chronic cholecystitis; 4. patients with complete clinical case information, including age, pre-treatment blood test results such as CA19-9 and other important clinical information; Healthy control group:; 1. voluntarily signed an informed consent form; 2. 18 years <= age <= 80 years; 3. no underlying disease and no abnormality in health examination.
Exclusion criteria
Exclusion criteria: 1.Comorbid Conditions: A documented history of malignancies involving other organ systems or hematologic diseases. 2.Treatment-Related Confounding Factors: Prior pancreatic surgery or receipt of tumor-related interventions, such as biliary drainage or chemotherapy/radiotherapy. 3.Sample Quality–Related Factors (Non-eligible Samples): Samples exhibiting severe hemolysis or marked lipemia. 4.Other Confounding Factors: Exclusion of patients with a history of blood transfusion or blood product administration within the past three months, to avoid interference from exogenous glycoproteins; exclusion of pregnant or breastfeeding women due to potential hormonal influences on biomarker expression; and exclusion of pancreatic cancer patients deemed unsuitable for participation in the study at the investigator’s discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum-derived extracellular vesicle-specific markers;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactBo Situ
Southern Medical University Southern Hospital
Outcome results
None listed